Payload Information
General Information of This Payload
| Payload ID | PAY0VRVTR |
|||||
|---|---|---|---|---|---|---|
| Name | A-1770637 |
|||||
| Target | DNA topoisomerase 1 (TOP1) | |||||
| Structure |
|
|||||
|
|
||||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Turmetabart adizutecan [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
21%
|
|||
| Patients Enrolled |
Eligible participants have ECOG 0-1, adequate organ function, QTc ≤450/470 msec (M/F), and measurable disease (RECIST 1.1/RANO). Parts 1-4 include R/R SCLC/CNS tumors/NECs progressing after SOC. Exclusions: ILD/pneumonitis, prior Top1-ADC therapy, or (Part 2) prior SEZ6-ADC. Fresh/archival tumor tissue is required for SEZ6 analysis.
|
||||
| Administration Dosage |
ABBV-706 was administered IV at 1.3-3.5 mg/kg doses Q3W in 21-d cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05599984 | Phase Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-706 as Monotherapy and in Combination With Budigalimab (ABBV-181), Carboplatin, or Cisplatin in Adult Subjects With Advanced Solid Tumors
|
||||
| Primary Endpoint |
Primary outcomes include AE incidence, PK parameters (Cmax, Tmax, t½, AUC), immunogenicity (ADA/nAb incidence), and tumor response metrics (ORR per RECIST 1.1/RANO, DOR, PFS, OS) assessed over ~2 years. The RP2D will be determined based on safety, PK, and efficacy data.
|
||||
ABBV-969 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
Eligible participants must have mCRPC with progression post-NHAs (abiraterone/enzalutamide) and prior taxane therapy, serum testosterone ≤50 ng/dL, measurable disease (RECIST 1.1/PCWG3), PSA ≥1 ng/mL, available tumor tissue, QTc ≤470 msec, and life expectancy >6 months.
|
||||
| Administration Dosage |
Participants will receive escalating doses of ABBV-969.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06318273 | Phase Status | PHASE1 | ||
| Clinical Description |
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer
|
||||
| Primary Endpoint |
The study evaluates safety through AE/SAE monitoring (up to 3 years) and efficacy via PSA response (≥50% decrease) in prostate cancer patients, with all events assessed by investigators for treatment relationship.
|
||||
| Other Endpoint |
Secondary endpoints include PK analysis of ABBV-969, and RP2D determination during dose-escalation (up to 2 years) based on safety/PK data.
|
||||
References